Dr Toh Chee Keong is an oncologist at Mount Elizabeth Novena Hospital, Singapore
He sub-specialises in thoracic oncology (lung cancer and thymic cancer), genitourinary oncology (prostate, kidney, bladder and testicular cancers) as well as head and neck cancers.
Dr Toh worked at the National Cancer Centre Singapore for most of his career, with a 3-year stint intercalated at Raffles Cancer Centre where he was director of clinical research before joining Curie Oncology. He was the lead of the Lung Cancer Consortium project at National Cancer Centre who coordinated lung cancer research in Singapore, paving the way for many publications and discoveries. He was also part of the team of the Large Collaborative Grant on ‘Next-Generation Clinical Trials and Integrative
Research for Fighting Lung Cancer’ awarded by National Medical Research Council.
Dr Toh graduated from National University of Singapore with the Gibbs Gold Medal in 1995, followed by MRCP (UK) in 2000 and specialist accreditation in Medical Oncology in 2004. Under the Health Manpower Development Programme, he was in the United States at Burnham Institute in La Jolla and Moores Cancer Centre in San Diego.
Throughout the years, he was involved in clinical work, clinical trials and teaching. Among his many achievements is his published work on the clinical characteristics of lung cancer among non-smokers, one of the earliest publications during a time when the molecular characteristic of this group of patients was not known yet. It was later discovered that lung cancer in non-smokers formed a big group in the Asian population.
Dr Toh was one of the earliest oncologists in Singapore to administer high dose interleukin-2 as a form of immunotherapy treatment for kidney cancer and melanoma. Immunotherapy then transitioned to checkpoint inhibitors over the years and became a cornerstone in the treatment of many cancers today. He has led and was a co-investigator in many clinical trials.
He was also a member in the workgroup for the Singapore Cancer Network (SCAN) guidelines for lung cancer, kidney cancer, prostate cancer and bladder cancer. In the area of teaching, he was assistant professor at the Yong Loo Lin School of Medicine, NUS and Duke-NUS medical school.